Amsterdam, The Netherlands, September 2, 2025 – EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company. The USD 44 million Series B financing round was led by EQT Life Sciences and co-led by Advent Life Sciences and British Business Bank (formerly British Patient Capital), with continued support from existing investors Morningside and BGF. The financing includes a non-dilutive contribution from a strategic partnership with HCA Healthcare. The financing will be used to accelerate the commercial expansion of Cyted's diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests.